Successful treatment of severe psoriasis in an adolescent with ustekinumab.
Psoriasis is a chronic, inflammatory, immune-mediated disease. Approximately 30% of patients have disease onset before age 18 years. Psoriasis in children and adolescents may be difficult to control, with subsequent poor quality of life and psychosocial consequences. We describe the case of a 12-year-old boy with severe, refractory, chronic plaque psoriasis for 6 years. Various therapeutic regimens including different topical corticosteroids, topical vitamin D analogs, phototherapy, photochemotherapy, systemic therapy with methotrexate, cyclosporin, and combination therapies showed only partial or transient responses with frequent relapses. Because anti-interleukin-12/23 agents have been successfully used in adults with psoriasis, ustekinumab was initiated and our patient showed a rapid, excellent, sustained response. No recurrence or flares have been observed after 33 months of follow-up. This case illustrates that ustekinumab may be an effective and safe therapeutic option in adolescents with psoriasis.
University of Toronto, Toronto, Ontario, Canada.
Mohn'd
M
AbuHilal
University of Toronto, Toronto, Ontario, Canada.
Nhung
N
Ho
D000293:Adolescent; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D000069549:Ustekinumab / Q000627:therapeutic use*
D003879:Dermatologic Agents; D000069549:Ustekinumab